~~<i id='7DE9DCBCB5'><strike id='7DE9DCBCB5'><tt id='7DE9DCBCB5'><pre id='7DE9DCBCB5'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：comprehensive 2025-10-06 08:33:49 Page View：14563

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What would happen to your eyes if you looked at the solar eclipse?
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

comprehensive

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Death of patient in Alzheimer’s trial raises question of possible risks

APSTockTheexperimentalAlzheimer’sdruglecanemab,hailedafteritslowedpatients’cognitivedeclineinaclinic